Christina M Hartman Orchard Therapeutics Linkedin The rapid growth of the cell and gene therapy (cgt) sector is revolutionizing disease treatment, but patients often face unique challenges in accessing these transformative therapies. She currently serves as the government affairs lead at orchard therapeutics, a rare disease gene therapy company. 4 prior to this, she held the position of senior director of advocacy at the assistance fund, where her annual compensation was $183,578 as of 2024. 5.
Christina M Hartman On Linkedin Rare Disease Conversations She also serves on the board of the us based rare disease non profit global genes. christina is an active supporter of research for and education about her daughter charlotte’s ultra rare neurodevelopmental disorder, naa10. At everylife foundation for rare diseases, she worked with global genes on the rare on the road program to get advocates, patients, and caregivers with rare diseases to capitol hill. Orchard’s in house lobbying hire reflects the growing importance of direct government engagement for gene therapy companies. with strong congressional interest in rare diseases but concerns about costs, the company is positioning itself for key reimbursement battles ahead. Christina hartman is no stranger to the world of science and medicine, but she was like any other parent when she was confronted with the reality that her child had a rare disease.
Christina M Hartman On Linkedin Raredisease Genetherapy Orchard’s in house lobbying hire reflects the growing importance of direct government engagement for gene therapy companies. with strong congressional interest in rare diseases but concerns about costs, the company is positioning itself for key reimbursement battles ahead. Christina hartman is no stranger to the world of science and medicine, but she was like any other parent when she was confronted with the reality that her child had a rare disease. Christina hartman, mph s as the senior director for government affairs at orchard therapeutics. she lives right outside washington, dc in bethesda, mary and with her husband, matt, and daughters sophie (12) and charlotte (7). before joining orchard, she led govern ent affairs for bluebird bio, another rare disease gene therapy company. she also. Our h1 2022 sector report is now available! 📰🧬 lnkd.in et p5y6 key takeaways: ️ there has never been more than 1 new #genetherapy approved for #raredisease in a single year. Exciting news in the medical community! the fda has approved the first gene therapy for children with metachromatic leukodystrophy (mld), a rare genetic disease affecting the brain and. Gene therapy represents a profound opportunity to improve the health and quality of life for patients with severe genetic diseases.
Christina M Hartman On Linkedin Nordsummit Christina hartman, mph s as the senior director for government affairs at orchard therapeutics. she lives right outside washington, dc in bethesda, mary and with her husband, matt, and daughters sophie (12) and charlotte (7). before joining orchard, she led govern ent affairs for bluebird bio, another rare disease gene therapy company. she also. Our h1 2022 sector report is now available! 📰🧬 lnkd.in et p5y6 key takeaways: ️ there has never been more than 1 new #genetherapy approved for #raredisease in a single year. Exciting news in the medical community! the fda has approved the first gene therapy for children with metachromatic leukodystrophy (mld), a rare genetic disease affecting the brain and. Gene therapy represents a profound opportunity to improve the health and quality of life for patients with severe genetic diseases.
Comments are closed.